BRPI0705784A2 - Uses of a Biopharmaceutical Containing a Expression of Mycobacterial Hsp65 Heat Shock Protein - Google Patents

Uses of a Biopharmaceutical Containing a Expression of Mycobacterial Hsp65 Heat Shock Protein

Info

Publication number
BRPI0705784A2
BRPI0705784A2 BRPI0705784A BRPI0705784A2 BR PI0705784 A2 BRPI0705784 A2 BR PI0705784A2 BR PI0705784 A BRPI0705784 A BR PI0705784A BR PI0705784 A2 BRPI0705784 A2 BR PI0705784A2
Authority
BR
Brazil
Prior art keywords
shock protein
biopharmaceutical
heat shock
expression
mycobacterial hsp65
Prior art date
Application number
Other languages
Portuguese (pt)
Inventor
Celio Lopes Silva
Adriana Ignacio De Paula
Jose Antonio Baddini Martinez
Lucia Helena Faccioli
Original Assignee
Univ Sao Paulo
Farmacore Biotecnologia Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sao Paulo, Farmacore Biotecnologia Ltda filed Critical Univ Sao Paulo
Priority to BRPI0705784 priority Critical patent/BRPI0705784A2/en
Publication of BRPI0705784A2 publication Critical patent/BRPI0705784A2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

USOS DE UMA COMPOSIçãO CONTENDO UM BIOFáRMACO EXPRESSANDO A PROTEìNA DE CHOQUE TéRMICO HSP65 DE MICOBACTéRIAS. A presente invenção trata do uso de uma composição de DNA contendo o gene da proteina de choque térmico (heat shock protein - HSP) de 65 KDa de micobactérias no preparo de um biofármaco para prevenção, tratamento e/ou cura de doenças inflamatórias, infecciosas e/ou fibróticas em seres humanos e animais. Particularmente, o presente pedido destina-se ao emprego do biofármaco na terapia da doença intersticial pulmonar (DIP).USES OF A COMPOSITION CONTAINING A BIOPHARMACY EXPRESSING THE HSP65 THERMAL SHOCK PROTEIN FROM MYCOBACTERIA. The present invention relates to the use of a DNA composition containing the 65 kDa heat shock protein (HSP) gene of mycobacteria in the preparation of a biopharmaceutical for the prevention, treatment and / or cure of inflammatory, infectious and inflammatory diseases. / or fibrotic in humans and animals. In particular, the present application is directed to the use of the biopharmaceutical in the therapy of interstitial lung disease (PID).

BRPI0705784 2007-08-17 2007-08-17 Uses of a Biopharmaceutical Containing a Expression of Mycobacterial Hsp65 Heat Shock Protein BRPI0705784A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0705784 BRPI0705784A2 (en) 2007-08-17 2007-08-17 Uses of a Biopharmaceutical Containing a Expression of Mycobacterial Hsp65 Heat Shock Protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0705784 BRPI0705784A2 (en) 2007-08-17 2007-08-17 Uses of a Biopharmaceutical Containing a Expression of Mycobacterial Hsp65 Heat Shock Protein

Publications (1)

Publication Number Publication Date
BRPI0705784A2 true BRPI0705784A2 (en) 2009-04-14

Family

ID=40612335

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0705784 BRPI0705784A2 (en) 2007-08-17 2007-08-17 Uses of a Biopharmaceutical Containing a Expression of Mycobacterial Hsp65 Heat Shock Protein

Country Status (1)

Country Link
BR (1) BRPI0705784A2 (en)

Similar Documents

Publication Publication Date Title
BR9909483A (en) Choline pneumococcal binding protein derivatives for vaccines
BRPI0509528A (en) human glp-1 imitation bodies, compositions, processes and uses
BRPI0416796A (en) organic compounds
BRPI0519241A2 (en) glp-1 agonists, compositions, methods and uses
BRPI0911874A2 (en) combined compositions for the treatment of alzheimer's disease and zonisamide and acamprosate related diseases
BRPI0811193A2 (en) ISOLATED ANTIGEN BINDING PROTEIN, NUCLEIC ACID, RECOMBINANT CELL, METHODS FOR PRODUCTING A PROTEIN AND FOR PROTECTING OR TREATING AGAINST S. AUREUS INFECTION IN PATIENT, PHARMACEUTICAL COMPOSITION, LYNAL PROTEIN AND POLYTEIN USE
BR112014026744A8 (en) isolated antibody or antibody fragment, antibody composition or antibody fragment composition, use of immune modulation, use of at least one antibody composition or antibody fragment, medical device, formulation, kit, article of manufacture for human pharmaceutical use, method for producing a transgenic antibody or fragment, animal or plant, and specified antibody or portion or variant.
BR112014000671A2 (en) methods for determining the content of a neuronally derived protein of interest, for determining the therapeutic efficacy of a therapeutic agent for treating alzheimer's disease, and for determining target coupling of a bound therapeutic antibody on a protein of interest for neuronal derivation
BRPI0821895A2 (en) PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF A DISEASE, A CONDITION AND SYMPTOMS OF THE SAME IN HOT BLOOD ANIMALS, INCLUDING HUMAN BEINGS, METHOD FOR PREPARATION OF THE PHARMACEUTICAL COMPOSITION, METHOD DIAGNOSIS
MX340231B (en) Hatching fluid enzymes and uses thereof.
BRPI0519135A2 (en) macrolides
BRPI1016208A2 (en) implant and therapeutic composition for the treatment of injuries and / or diseases related to the human and / or animal musculoskeletal system
BRPI0514124B8 (en) monoclonal antibodies specific for human il-4, their use, pharmaceutical composition comprising them, and polynucleotides
Roslan et al. Recent advances in single-cell engineered live biotherapeutic products research for skin repair and disease treatment
BRPI0509271A (en) gastro-resistant pharmaceutical dosage forms comprising n- (2- (2-phthalimideethoxy) -acetyl-1-alanyl-d-glutamic acid (lk-4 23)
BRPI0705784A2 (en) Uses of a Biopharmaceutical Containing a Expression of Mycobacterial Hsp65 Heat Shock Protein
GT200600209A (en) TREATMENT OF DISEASES USING AN IMPROVED REGULATED EXPRESSION SYSTEM
PT1133997E (en) BETA-INTERFERENCE FOR THE TREATMENT OF IMMUNE DISEASES
CY1115322T1 (en) TRIGONELLA EXTRACT FOR HUMAN DISEASE TREATMENT AND ANIMALS IN WHICH MASTERFUL PARASITES ARE INVOLVED
CR11384A (en) STREPTOCOCO PROTEIN M, IMMUNOGENIC FRAGMENTS, NUCLEIC ACIDS AND METHODS OF USE
BRPI0616492B8 (en) uses of a guar protein extract
Quel et al. Cellulitis lesions in broiler chickens are induced by Escherichia coli Vacuolating Factor (ECVF)
EA201600347A3 (en) HYBRID PROTEIN, DNA, GENETIC CONSTRUCTION, PRODUCER, VACCINE BASED ON HYBRID PROTEIN FOR PREVENTION AND TREATMENT OF TUBERCULOSIS (OPTIONS)
DOP2006000117A (en) INTERFERON-BETA GENE THERAPY USING AN IMPROVED REGULATED EXPRESSION SYSTEM
WO2007134907A3 (en) Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15G Others concerning applications: unknown petition

Free format text: NAO CONHECIDA A PETICAO NO870180129201 DE 12/09/2018, EM VIRTUDE DO DISPOSTO NO ARTO219 INCISO III DA LPI

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: VIDE PARECER